{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:24:32Z","timestamp":1771064672264,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bulcan.2023.02.005","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T08:05:37Z","timestamp":1677744337000},"page":"424-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prise en charge des LAM chez les sujets \u00e2g\u00e9s"],"prefix":"10.1016","volume":"110","author":[{"given":"Pierre-Yves","family":"Dumas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bulcan.2023.02.005_bib0180","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2023.02.005_bib0185","doi-asserted-by":"crossref","first-page":"12475","DOI":"10.1038\/ncomms12475","article-title":"Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia","volume":"7","author":"Hirsch","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2023.02.005_bib0190","author":"Le Guyader-Peyrou","year":"2019","journal-title":"Sante Publique Fr"},{"issue":"1","key":"10.1016\/j.bulcan.2023.02.005_bib0195","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1038\/s41598-019-48445-1","article-title":"An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States","volume":"9","author":"Hao","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.005_bib0200","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022\u00a0recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.005_bib0205","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.005_bib0210","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876\u00a0younger adult patients treated in the United Kingdom medical research council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bulcan.2023.02.005_bib0215","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2023.02.005_bib0220","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998\u00a0patients age 65\u00a0years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2023.02.005_bib0225","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60\u00a0years of age receiving induction therapy for acute myeloid leukaemia","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.bulcan.2023.02.005_bib0230","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.005_bib0235","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3324\/haematol.13309","article-title":"Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia","volume":"93","author":"Malfuson","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bulcan.2023.02.005_bib0240","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2023.02.005_bib0250","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood.V118.21.3594.3594","article-title":"Impact of NPM1, FLT3, and RAS mutations on the outcomes of elderly patients with acute myeloid leukemia","volume":"118","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2023.02.005_bib0255","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2023.02.005_bib0260","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bulcan.2023.02.005_bib0265","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.005_bib0270","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3\u00a0study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30\u00a0% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2023.02.005_bib0275","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.02.005_bib0280","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.005_bib0285","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bulcan.2023.02.005_bib0290","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3\u00a0randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2023.02.005_bib0295","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.V58.6.1203.1203","article-title":"Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B","volume":"58","author":"Rai","year":"1981","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.bulcan.2023.02.005_bib0300","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.2018.78.7366","article-title":"Improved survival by adding lomustine to conventional chemotherapy for elderly patients With AML without unfavorable cytogenetics: results of the LAM-SA 2007\u00a0FILO trial","volume":"36","author":"Pigneux","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.02.005_bib0305","article-title":"Lomustine is beneficial to older AML with ELN2017\u00a0adverse risk profile and intermediate karyotype: a FILO study","volume":"1\u201310","author":"Largeaud","year":"2020","journal-title":"Leukemia"},{"issue":"9825","key":"10.1016\/j.bulcan.2023.02.005_bib0310","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3\u00a0study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"10.1016\/j.bulcan.2023.02.005_bib0315","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2023.02.005_bib0320","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3\u00a0mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.005_bib0325","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3\u00a0inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2\u00a0trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2023.02.005_bib0330","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bulcan.2023.02.005_bib0335","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.bulcan.2023.02.005_bib0340","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2023.02.005_bib0350","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/bloodadvances.2021004435","article-title":"In-depth time-dependent analysis of the benefit of Allo-HSCT for elderly patients with CR1\u00a0AML: a FILO study","volume":"6","author":"Devillier","year":"2021","journal-title":"Blood Adv"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:33Z","timestamp":1757792253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0007455123000784"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des LAM chez les sujets \u00e2g\u00e9s","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}